Top Journal Scans

Kim A. Eagle, MD, MACC
Editor-in-Chief, ACC.org

In 2022 with much of the care landscape returning to more normalcy after the COVID-19 pandemic eased, we saw the most visited journal scan content on ACC.org once again focused on common areas of cardiovascular practice and areas with advances in therapy. ACC.org is a home for condensed, digestible content particularly around important summary documents like the guidelines and consensus statements. In 2022, we saw release of new heart failure guidelines, new guidelines for the evaluation of cardiovascular disorders prior to non-cardiac surgery and for pulmonary hypertension, a summary statement on the use of aspirin for primary prevention, and a state-of-the-art summary on rhythm control for atrial fibrillation. The ACC looks forward to an exciting 2023 and the opportunity to continue to partner with you in the provision of "state of the art" information for your practice!

— Kim A. Eagle, MD, MACC

• 2022 AHA/ACC/HFSA Heart Failure Guideline: Key Perspectives
• Review on LV Thrombus Following MI
• 2022 ESC Guidelines for CV Assessment of Noncardiac Surgery
• 2022 ESC/ERS Guidelines for Pulmonary Hypertension
• The Increasing Role of Rhythm Control in Atrial Fibrillation
• USPSTF Report on Aspirin for Primary Prevention
• Management of Patients at Risk for and With LV Thrombus
• Myocarditis After COVID-19 Vaccine
• Major Global Coronary Artery Calcium Guidelines
• Mineralocorticoid Receptor Antagonists and Empagliflozin in HFpEF

Top Clinical Trials

Deepak L. Bhatt, MD, MPH, FACC
Senior Associate Editor, Clinical Trials and News, ACC.org

It was another great year for trial coverage on ACC.org! There were almost 140,000 unique views of the top 10 trials and top 10 trial updates for the year. Treatment of heart failure and of hypertrophic cardiomyopathy were hot topics. In addition to covering new trials, we update prior trials with any related significant presentations or publications. We have added new features for our learners to make clear what is updated compared with the prior version of a clinical trial summary. Hopefully, this change allows quicker reading of these trial synopses. Interestingly, some of the trial updates had more views than de novo trial coverage. We have also started providing visual abstracts for some of the key trials at the major meetings. We are striving to make ACC.org a very user-friendly educational portal. On behalf of the ACC.org staff, Happy Holidays, and a joyous New Year to you all!

— Deepak L. Bhatt, MD, MPH, FACC

Top Clinical Trials

• VALOR HCM: Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy
• TRANSFORM-HF: Torsemide Comparison With Furosemide for Management of Heart Failure
• ADVOR: Acetazolamide in Decompensated Heart Failure With Volume Overload
• INVICTUS: Investigation of Rheumatic AFib Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies
• PACMAN-AMI: Effects of the PCSK9 Antibody Alirocumab on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction
• DIAMOND: Patiromer For the Management of Hyperkalemia in Subjects Receiving RAASi for HFrEF
• EARLY-AF: Early Aggressive Invasive Intervention for Atrial Fibrillation
• FLAVOUR: Fractional Flow Reserve and Intravascular Ultrasound-Guided Intervention Strategy For Clinical Outcomes in Patients With Intermediate Stenosis
• IRONMAN: Effectiveness of Intravenous Iron Treatment Versus Standard Care in Patients With Heart Failure and Iron Deficiency
• CHAP: Chronic Hypertension and Pregnancy

Top Clinical Trial Updates

• EXPLORER-HCM (Update): Mavacamten for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy
• EMPULSE (Update): Empagliflozin in Patients Hospitalized for Acute Heart Failure
• DAPA-HF (Update): Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction
• ISCHEMIA (Update): International Study of Comparative Health Effectiveness With Medical and Invasive Approaches
• TWILIGHT (Update): Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention
• EMPEROR REDUCED (Update): Empagliflozin Outcome Trial in Patients With Chronic Heart Failure and a Reduced Ejection Fraction
• REDUCE-IT (Update): Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial
• PARAGON-HF (Update): Prospective Comparison of ARNI With ARB Global Outcomes in HF With Preserved Ejection Fraction
• COAPT (Update): Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation
• COMPLETE (Update): Complete Versus Culprit-Only Revascularization Strategies to Treat Multivessel Disease After Early PCI for STEMI

Clinical Topics: Acute Coronary Syndromes, Anticoagulation Management, Arrhythmias and Clinical EP, Atherosclerotic Disease (CAD/PAD), Cardiac Surgery, Cardio-Oncology, Cardiovascular Care Team, Congenital Heart Disease and Pediatric Cardiology, COVID-19 Hub, Dyslipidemia, Geriatric Cardiology, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Noninvasive Imaging, Pericardial Disease, Prevention, Pulmonary Hypertension and Venous Thromboembolism, Sports and Exercise Cardiology, Stable Ischemic Heart Disease, Valvular Heart Disease, Vascular Medicine, Diabetes and Cardiometabolic Disease

< Back to Listings